Cell surface targeting accounts for the difference in iodide uptake activity between human Na+/I- symporter and rat Na+/I- symporter

被引:20
作者
Zhang, ZX [1 ]
Liu, YY
Jhiang, SM
机构
[1] Ohio State Univ, Coll Med, Ohio State Biochem Program, Dept Physiol, Columbus, OH 43210 USA
[2] Ohio State Univ, Coll Med, Ohio State Biochem Program, Dept Cell Biol, Columbus, OH 43210 USA
[3] Ohio State Univ, Coll Med, Ohio State Biochem Program, Dept Internal Med, Columbus, OH 43210 USA
关键词
D O I
10.1210/jc.2005-0895
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: The Na (+)/I- symporter (NIS) has been proposed to serve as an imaging reporter gene to optimize vector delivery, monitor therapeutic gene expression, and map the tissue/organ sites of repopulated progenitor cells in vivo. In addition, NIS can serve as a therapeutic gene to facilitate targeted radionuclide therapy for various cancers. Objective: It was reported that rat NIS (rNIS) confers higher radioactive iodide uptake (RAIU) activity than human NIS (hNIS). We aim to investigate the mechanism underlying this difference. Results: We showed that the open reading frames (ORF) of hNIS and rNIS, although encoding for proteins with 83% amino acid identity, exhibit a significant difference in RAIU activity in transfected cells. The ORF rNIS confers four to five times higher RAIU activity as well as cell surface NIS accumulation than ORF hNIS despite similar total NIS protein levels. Multiple regions appear to play roles in the difference in NIS cell surface levels between ORF hNIS and ORF rNIS, indicating that proper folding of NIS in tertiary structure is critical for NIS cell surface targeting. We also showed that the kinetics of Na+ binding are different between ORF hNIS and ORF rNIS, and that site-directed mutation changing Ser200 to other uncharged amino acid significantly increased RAIU activity in ORF hNIS. Conclusions: NIS transgene could be optimized for cell surface trafficking and RAIU activity to improve its clinical applications.
引用
收藏
页码:6131 / 6140
页数:10
相关论文
共 39 条
[1]  
Boland A, 2000, CANCER RES, V60, P3484
[2]   Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: Correlation with radioiodine uptake [J].
Castro, MR ;
Bergert, ER ;
Goellner, JR ;
Hay, ID ;
Morris, JC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (11) :5627-5632
[3]   In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas [J].
Cho, JY ;
Shen, DHY ;
Yang, W ;
Williams, B ;
Buckwalter, T ;
La Perle, KMD ;
Hinkle, G ;
Pozderac, R ;
Kloos, R ;
Nagaraja, H ;
Barth, RF ;
Jhiang, SM .
GENE THERAPY, 2002, 9 (17) :1139-1145
[4]  
Chung JK, 2002, J NUCL MED, V43, P1188
[5]   Cloning and characterization of the thyroid iodide transporter [J].
Dai, G ;
Levy, O ;
Carrasco, N .
NATURE, 1996, 379 (6564) :458-460
[6]   The Q267E mutation in the sodium/iodide symporter (NIS) causes congenital iodide transport defect (ITD) by decreasing the NIS turnover number [J].
De la Vleja, A ;
Ginter, CS ;
Carrasco, N .
JOURNAL OF CELL SCIENCE, 2004, 117 (05) :677-687
[7]  
DELAVIEJA A, 2000, TOPOLOGY SODIUM IODI, P162
[8]   Na+/I- symporter activity requires a small and uncharged amino acid residue at position 395 [J].
Dohán, O ;
Gavrielides, MV ;
Ginter, C ;
Amzel, LM ;
Carrasco, N .
MOLECULAR ENDOCRINOLOGY, 2002, 16 (08) :1893-1902
[9]   Thyroid Na+/I- symporter - Mechanism, stoichiometry, and specificity [J].
Eskandari, S ;
Loo, DDF ;
Dai, G ;
Levy, O ;
Wright, EM ;
Carrasco, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (43) :27230-27238
[10]   Recurrent T354P mutation of the Na+/I- symporter in patients with iodide transport defects [J].
Fujiwara, H ;
Tatsumi, K ;
Miki, K ;
Harada, T ;
Okada, S ;
Nose, O ;
Kodama, S ;
Amino, N .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (08) :2940-2943